Lv21
106 积分 2023-10-27 加入
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
2小时前
已完结
"Beyond the Genetic Blueprint: Disrupting the Epitranscriptomic Code in Myeloproliferative Neoplasms"
5天前
已完结
Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs
6天前
已完结
The next 25 years of cancer research: emerging perspectives and priorities
24天前
已完结
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
27天前
已完结
Classic Hodgkin Lymphoma: A Review
28天前
已完结
At the heart of unmet need: TP53 myeloid neoplasms
28天前
已关闭
At the heart of unmet need: TP53 myeloid neoplasms
28天前
已关闭
Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?
29天前
已完结
Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
1个月前
已完结
皖公网安备34019202002308
